KarXT

Phase 3

Bristol-Myers Squibb Company (BMY)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Nov '26

BMYPhase 3$126.6B

KarXT Phase 3 Est. Readout

KarXT• Bipolar-I Disorder With Mania or Mania With Mixed Features274

Nov 2026~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Bipolar-I Disorder With Mania or Mania With Mixed Features

View Full Landscape

Drug Information

Target Indication

Bipolar-I Disorder With Mania or Mania With Mixed Features

Clinical Trial

NCT06951698

Last updated: 1/22/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

BMY

Bristol-Myers Squibb Company

Pharmaceutical Preparations•North America•NYSE

Related Pipeline

adefovirPhase 3

Hepatitis B

VinfluninePhase 3

Bladder Cancer

BMS-936558 (Nivolumab)Phase 3

Melanoma

DCV/ASV/BMS-791325Phase 3

Hepatitis C

BMS-986489 (BMS-986012+Nivolumab)Phase 3

Extensive-Stage Small Cell Lung Cancer

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts